Stronger prognostic power of the CpG island methylator phenotype than methylation of individual genes in neuroblastomas

Japanese Journal of Clinical Oncology

Volumn 43, Issue 6, 2013, Pages 641-645

  Asada, Kiyoshi ^a   Watanabe, Naoko ^a   Nakamura, Yohko ^b   Ohira, Miki ^b   Westermann, Frank ^c   Schwab, Manfred ^c   Nakagawara, Akira ^b   Ushijima, Toshikazu ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b CHIBA CANCER CENTER   (Japan)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

CIMP; Methylation; Neuroblastoma; Poor survival

Indexed keywords

HERMES ANTIGEN; TRANSCRIPTION FACTOR HOXA9;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CPG ISLAND; GENE; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; JAPANESE; MAJOR CLINICAL STUDY; METHYLATION; NEUROBLASTOMA; OVERALL SURVIVAL; PHENOTYPE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; SURVIVAL TIME;

CIMP; METHYLATION; NEUROBLASTOMA; POOR SURVIVAL;

ANTIGENS, CD44; ASIAN CONTINENTAL ANCESTRY GROUP; CASPASE 8; CONFIDENCE INTERVALS; CPG ISLANDS; DNA METHYLATION; HOMEODOMAIN PROTEINS; HUMANS; KAPLAN-MEIER ESTIMATE; MEMBRANE GLYCOPROTEINS; NEUROBLASTOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROMOTER REGIONS, GENETIC; RECEPTORS, STEROID;

EID: 84878642565     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyt058     Document Type: Article

References (24)

1. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007;369:2106-20.
2. Abe M, Ohira M, Kaneda A, et al. CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. Cancer Res 2005;65:828-34.
3. Abe M,Westermann F, Nakagawara A, Takato T, Schwab M, Ushijima T. Marked and independent prognostic significance of the CpG island methylator phenotype in neuroblastomas. Cancer Lett 2007;247:253-8.
4. Banelli B, Brigati C, Di Vinci A, et al. A pyrosequencing assay for the quantitative methylation analysis of the PCDHB gene cluster, the major factor in neuroblastoma methylator phenotype. Lab Invest 2011;92:458-65.
5. Schwab M, Alitalo K, Klempnauer KH, et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983;305:245-8.
6. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-4.
7. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111-6.
8. Ushijima T, Watanabe N, Okochi E, Kaneda A, Sugimura T, Miyamoto K. Fidelity of the methylation pattern and its variation in the genome. Genome Res 2003;13:868-74.
9. Grau E, Martinez F, Orellana C, et al. Hypermethylation of apoptotic genes as independent prognostic factor in neuroblastoma disease. Mol Carcinog 2011;50:153-62.
10. Misawa A, Inoue J, Sugino Y, et al. Methylation-associated silencing of the nuclear receptor 1I2 gene in advanced-type neuroblastomas, identified by bacterial artificial chromosome array-based methylated CpG island amplification. Cancer Res 2005;65:10233-42.
11. Alaminos M, Davalos V, Ropero S, et al. EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma. Cancer Res 2005;65:2565-71.
12. Alaminos M, Davalos V, Cheung NK, Gerald WL, Esteller M. Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. J Natl Cancer Inst 2004;96:1208-19.
13. Teitz T, Wei T, Valentine MB, et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000;6:529-35.
14. Kaneda A, Kaminishi M, Sugimura T, Ushijima T. Decreased expression of the seven ARP2/3 complex genes in human gastric cancers. Cancer Lett 2004;212:203-10.
15. Margetts CD, Morris M, Astuti D, et al. Evaluation of a functional epigenetic approach to identify promoter region methylation in phaeochromocytoma and neuroblastoma. Endocr Relat Cancer 2008;15:777-86.
16. Hoebeeck J, Michels E, Pattyn F, et al. Aberrant methylation of candidate tumor suppressor genes in neuroblastoma. Cancer Lett 2009;273:336-46.
17. Yang Q, Kiernan CM, Tian Y, et al. Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome. Clin Cancer Res 2007;13:3191-7.
18. Lau DT, Hesson LB, Norris MD, Marshall GM, Haber M, Ashton LJ. Prognostic significance of promoter DNA methylation in patients with childhood neuroblastoma. Clin Cancer Res 2012;18:5690-700.
19. Michalowski MB, de Fraipont F, Plantaz D, Michelland S, Combaret V, Favrot MC. Methylation of tumor-suppressor genes in neuroblastoma: the RASSF1A gene is almost always methylated in primary tumors. Pediatr Blood Cancer 2008;50:29-32.
20. Kamimatsuse A, Matsuura K, Moriya S, et al. Detection of CpG island hypermethylation of caspase-8 in neuroblastoma using an oligonucleotide array. Pediatr Blood Cancer 2009;52:777-83.
21. Yang Q, Zage P, Kagan D, et al. Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma. Clin Cancer Res 2004;10:8493-500.
22. Banelli B, Gelvi I, Di Vinci A, et al. Distinct CpG methylation profiles characterize different clinical groups of neuroblastic tumors. Oncogene 2005;24:5619-28.
23. Banelli B, Bonassi S, Casciano I, et al. Outcome prediction and risk assessment by quantitative pyrosequencing methylation analysis of the SFN gene in advanced stage, high-risk, neuroblastic tumor patients. Int J Cancer 2010;126:656-68.
24. Buckley PG, Das S, Bryan K, et al. Genome-wide DNA methylation analysis of neuroblastic tumors reveals clinically relevant epigenetic events and large-scale epigenomic alterations localized to telomeric regions. Int J Cancer 2011;128:2296-305.